PURPOSE: To determine whether shortening the infusion duration of high-dose methotrexate (HDMTX; 1 g/m(2)) affects the in vivo accumulation of active methotrexate polyglutamates (MTXPG(1-7)) in leukemia cells and whether this differs among major acute lymphoblastic leukemia (ALL) subtypes. METHODS:From June 2000 through October 2007, 356 children with ALL were randomly assigned to receive initial single-agent treatment with HDMTX (1 g/m(2)) as either a 24-hour infusion or a 4-hour infusion at two pediatric hospitals in the United States. The primary outcome measures were the accumulation of MTXPG(1-7) in leukemia cells and the antileukemic effects (eg, inhibition of de novo purine synthesis in bone marrow ALL cells, and decrease in circulating ALL cells). RESULTS: The 24-hour infusion resulted in significantly higher amounts of MTXPG(1-7) in bone marrow leukemia cells (median: 1,695 v 1,150 pmol/10(9) cells, P = .0059), and better antileukemic effects. The 24-hour infusion had the greatest effect on MTXPG(1-7) accumulation in hyperdiploid ALL (median: 3,919 v 2,417 pmol/10(9) cells, P = .0038); T-cell ALL exhibited smaller differences in MTXPG(1-7) but greater antileukemic effects with the longer infusion (median decrease in leukemia cells: 88.4% v 51.8%, P = .0075). In contrast, infusion duration had no significant impact on MTXPG(1-7) accumulation or antileukemic effects in ALL with the t(12;21)/(ETV6-RUNX1) chromosomal translocation. CONCLUSION: Shortening the infusion time of HDMTX reduces accumulation of active methotrexate in leukemia cells and decreases antileukemic effects, with differing consequences among major ALL subtypes.
RCT Entities:
PURPOSE: To determine whether shortening the infusion duration of high-dose methotrexate (HDMTX; 1 g/m(2)) affects the in vivo accumulation of active methotrexate polyglutamates (MTXPG(1-7)) in leukemia cells and whether this differs among major acute lymphoblastic leukemia (ALL) subtypes. METHODS: From June 2000 through October 2007, 356 children with ALL were randomly assigned to receive initial single-agent treatment with HDMTX (1 g/m(2)) as either a 24-hour infusion or a 4-hour infusion at two pediatric hospitals in the United States. The primary outcome measures were the accumulation of MTXPG(1-7) in leukemia cells and the antileukemic effects (eg, inhibition of de novo purine synthesis in bone marrow ALL cells, and decrease in circulating ALL cells). RESULTS: The 24-hour infusion resulted in significantly higher amounts of MTXPG(1-7) in bone marrow leukemia cells (median: 1,695 v 1,150 pmol/10(9) cells, P = .0059), and better antileukemic effects. The 24-hour infusion had the greatest effect on MTXPG(1-7) accumulation in hyperdiploid ALL (median: 3,919 v 2,417 pmol/10(9) cells, P = .0038); T-cell ALL exhibited smaller differences in MTXPG(1-7) but greater antileukemic effects with the longer infusion (median decrease in leukemia cells: 88.4% v 51.8%, P = .0075). In contrast, infusion duration had no significant impact on MTXPG(1-7) accumulation or antileukemic effects in ALL with the t(12;21)/(ETV6-RUNX1) chromosomal translocation. CONCLUSION: Shortening the infusion time of HDMTX reduces accumulation of active methotrexate in leukemia cells and decreases antileukemic effects, with differing consequences among major ALL subtypes.
Authors: A J Galpin; J D Schuetz; E Masson; Y Yanishevski; T W Synold; J C Barredo; C H Pui; M V Relling; W E Evans Journal: Mol Pharmacol Date: 1997-07 Impact factor: 4.436
Authors: Valentino Conter; Maria Grazia Valsecchi; Daniela Silvestri; Myriam Campbell; Eduardo Dibar; Edina Magyarosy; Helmut Gadner; Jan Stary; Yves Benoit; Martin Zimmermann; Alfred Reiter; Hansjörg Riehm; Giuseppe Masera; Martin Schrappe Journal: Lancet Date: 2007-01-13 Impact factor: 79.321
Authors: J H Hooijberg; H J Broxterman; M Kool; Y G Assaraf; G J Peters; P Noordhuis; R J Scheper; P Borst; H M Pinedo; G Jansen Journal: Cancer Res Date: 1999-06-01 Impact factor: 12.701
Authors: Leo Kager; Meyling Cheok; Wenjian Yang; Gianluigi Zaza; Qing Cheng; John C Panetta; Ching-Hon Pui; James R Downing; Mary V Relling; William E Evans Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: M G Rots; R Pieters; G J Peters; P Noordhuis; C H van Zantwijk; G J Kaspers; K Hählen; U Creutzig; A J Veerman; G Jansen Journal: Blood Date: 1999-03-01 Impact factor: 22.113
Authors: Mignon L Loh; Meredith A Goldwasser; Lewis B Silverman; Wing-Man Poon; Shashaank Vattikuti; Angelo Cardoso; Donna S Neuberg; Kevin M Shannon; Stephen E Sallan; D Gary Gilliland Journal: Blood Date: 2006-02-21 Impact factor: 22.113
Authors: Elixabet Lopez-Lopez; Robert J Autry; Colton Smith; Wenjian Yang; Steven W Paugh; John C Panetta; Kristine R Crews; Erik J Bonten; Brandon Smart; Deqing Pei; J Robert McCorkle; Barthelemy Diouf; Kathryn G Roberts; Lei Shi; Stanley Pounds; Cheng Cheng; Charles G Mullighan; Ching-Hon Pui; Mary V Relling; William E Evans Journal: J Clin Invest Date: 2020-12-01 Impact factor: 14.808
Authors: M A H den Hoed; E Lopez-Lopez; M L te Winkel; W Tissing; J D E de Rooij; A Gutierrez-Camino; A Garcia-Orad; E den Boer; R Pieters; S M F Pluijm; R de Jonge; M M van den Heuvel-Eibrink Journal: Pharmacogenomics J Date: 2014-11-04 Impact factor: 3.550
Authors: Laura B Ramsey; John C Panetta; Colton Smith; Wenjian Yang; Yiping Fan; Naomi J Winick; Paul L Martin; Cheng Cheng; Meenakshi Devidas; Ching-Hon Pui; William E Evans; Stephen P Hunger; Mignon Loh; Mary V Relling Journal: Blood Date: 2012-12-11 Impact factor: 22.113
Authors: Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544